Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2022-11-07 Regulatory Filings
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox : Plans de développement et de partenariat pour le NCX 470 dans le glaucome
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and is dated November 7, 2022. It details corporate plans, clinical trial updates (Phase 3 Mont Blanc and Denali for NCX 470), partnership strategies (US and Japan), and financial runway related to these developments. This content structure—announcing key operational and clinical milestones via a press release format—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses heavily on clinical progress and future strategy rather than just summarizing period-end financial results (which would lean towards ER), and it is not a formal regulatory filing like a 10-K or a detailed management discussion (MDA), it fits best as an Earnings Release (ER) which often includes operational updates, or potentially a Regulatory Filing (RNS) if it were less specific. Given the detailed operational and clinical update nature, ER is a strong candidate, but since it is a general corporate announcement about development plans and partnerships rather than a mandated periodic financial result announcement, it aligns well with the general nature of a Regulatory Filing (RNS) which serves as a broad category for important, non-standardized corporate news, or potentially an Investor Presentation (IP) if it were structured as slides, but it is a text release. However, press releases detailing significant operational updates, especially those concerning clinical trial progress and strategic outlook, are frequently categorized as Earnings Releases (ER) when they are issued around reporting periods, or as Regulatory Filings (RNS) if they are purely informational announcements. Given the focus on development plans and partnership optimization, and the lack of explicit quarterly/annual financial summary headers typical of a formal ER, RNS is the most appropriate fallback for a significant, non-standardized corporate announcement. If the document were purely a summary of financial results, ER would be chosen. Since it's a strategic update announced via press release, RNS is safer as a general regulatory announcement.
2022-11-07 French
NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE AU 31 OCTOBRE 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "PUBLICATION MENSUELLE DU NOMBRE D'ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE" (Monthly publication of the number of shares comprising the capital and the total number of voting rights). It explicitly references French regulatory articles (Code de Commerce and AMF regulations) and provides a snapshot of the total shares and voting rights as of October 31, 2022. This type of periodic disclosure regarding share capital and voting rights, especially when published monthly, does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure concerning share structure. Since there is no specific code for 'Monthly Share Capital Disclosure', the most appropriate general category for mandatory, non-financial-statement regulatory updates that don't fit elsewhere is 'Regulatory Filings' (RNS). It is not a report publication announcement (RPA) because it *is* the required disclosure, not an announcement *about* another report.
2022-11-02 French
Publication of the Number of Shares Composing the Share Capital and of the Total Number of Voting Rights AS OF OCTOBER 31, 2022
Share Issue/Capital Change Classification · 99% confidence The document explicitly states it is a 'MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS' as of October 31, 2022, referencing French commercial code and AMF regulations. This type of regular disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement, often related to capital structure updates or mandatory periodic disclosures. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). While it relates to capital, it is a mandatory disclosure of the current count, not a financing activity (CAP) or a share repurchase (POS). Given the options, this mandatory periodic disclosure of share capital and voting rights aligns most closely with a general regulatory filing or a specific capital structure update. Since there isn't a specific code for 'Share Capital/Voting Rights Publication', and it is a mandatory regulatory disclosure, it fits best under the general 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA) if interpreted broadly. However, since it is a recurring, mandatory disclosure of the *current state* of capital/rights, and not an announcement of a *change* (like a new issue or buyback), RNS is the most appropriate fallback for a specific regulatory disclosure not covered elsewhere. The document length is short, but it is the report itself, not an announcement of a report, so RPA/RNS is appropriate for the filing type.
2022-11-02 English
Nicox : NCX 470 atteint l’objectif primaire de l’étude Mont Blanc, la première étude de phase 3 sur le NCX 470 dans le glaucome
Earnings Release Classification · 99% confidence The document is titled "Press Release" and announces clinical trial results (Phase 3 study 'Mont Blanc' for drug NCX 470). It details efficacy endpoints, safety profiles, and future study plans (Denali). This type of announcement, focusing on key periodic results (clinical trial milestones) released via a press release, aligns best with an Earnings Release (ER) if it were quarterly financial results, or a Regulatory Filing (RNS) if it were a general announcement. However, since it is a detailed announcement of scientific/clinical progress, it is often categorized as a specific type of corporate update. Given the options, it is not a formal 10-K, AR, or IR. It is a major corporate update announcing a significant milestone, which often accompanies or precedes formal regulatory filings. Since it is a detailed press release announcing clinical trial success, it functions as a major corporate disclosure. It is not a Call Transcript (CT), Investor Presentation (IP), or a simple Dividend Notice (DIV). Because it is a detailed announcement of results rather than a short notice of publication, it is not RPA. It is a significant corporate event disclosure. In the context of financial reporting databases, major clinical trial updates are often classified under general Regulatory Filings (RNS) if no other specific category fits, or sometimes grouped with Earnings Releases (ER) if they are tied to a reporting period, but this is purely clinical data. Given the options, RNS is the most appropriate fallback for a significant, non-standard regulatory/corporate announcement that isn't a standard financial report or management change. FY 2022
2022-10-31 French
Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled "# **Press Release**" and announces the topline results of a Phase 3 clinical trial (Mont Blanc) for a drug candidate (NCX 470). It provides key efficacy and safety data points, quotes from the CEO and CSO, and outlines the design of ongoing trials. This format—a formal announcement of key periodic operational/clinical results, often released before a full quarterly or annual report—is characteristic of an Earnings Release (ER) or a significant operational update. Since it focuses on clinical trial success/failure and key metrics rather than comprehensive financial statements for a full period, it aligns best with the 'Earnings Release' definition, which covers initial announcements of periodical financial/operational results.
2022-10-31 English
Nicox : Résumé financier et point d’activité du troisième trimestre 2022
Earnings Release Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and provides a "Résumé financier et point d'activité du troisième trimestre 2022" (Financial summary and business update for the third quarter of 2022). It highlights key financial figures (net revenue, cash position) and operational milestones (clinical trial updates, prescription growth) for a specific interim period (Q3 2022). This structure—a brief announcement focusing on key performance indicators for a recent quarter—is characteristic of an Earnings Release (ER). It is not the full, comprehensive report (like an IR or 10-K), nor is it a transcript (CT) or a management discussion (MDA), although it contains elements of both. It is the initial announcement of period results. Q3 2022
2022-10-19 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.